A multicentre, randomised, open-label, parallel-group trial to study the safety and non-inferiority of a new therapeutic strategy (the Fuster-CNIC-Ferrer cardiovascular polypill) versus usual care on LDLc and blood pressure reduction in patients with atherothrombotic cardiovascular disease: The APOLO trial.

Trial Profile

A multicentre, randomised, open-label, parallel-group trial to study the safety and non-inferiority of a new therapeutic strategy (the Fuster-CNIC-Ferrer cardiovascular polypill) versus usual care on LDLc and blood pressure reduction in patients with atherothrombotic cardiovascular disease: The APOLO trial.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Feb 2018

At a glance

  • Drugs Aspirin/atorvastatin/ramipril (Primary)
  • Indications Hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms APOLO
  • Sponsors Ferrer
  • Most Recent Events

    • 09 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top